share_log

Atea Pharmaceuticals Analyst Ratings

Atea Pharmaceuticals Analyst Ratings

雅泰醫藥分析師評級
Benzinga Analyst Ratings ·  2023/01/27 19:51
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/27/2023 31.29% SVB Leerink $8 → $6 Maintains Market Perform
01/24/2023 -12.47% Morgan Stanley $7 → $4 Maintains Underweight
08/15/2022 53.17% Morgan Stanley $6 → $7 Maintains Underweight
03/02/2022 75.05% JP Morgan $10 → $8 Maintains Neutral
03/01/2022 96.94% SVB Leerink $10 → $9 Maintains Market Perform
02/16/2022 118.82% SVB Leerink $11 → $10 Maintains Market Perform
01/06/2022 53.17% Morgan Stanley $14 → $7 Downgrades Equal-Weight → Underweight
11/18/2021 140.7% SVB Leerink → $11 Downgrades Outperform → Market Perform
10/20/2021 337.64% SVB Leerink $60 → $20 Maintains Outperform
10/20/2021 250.11% JP Morgan $61 → $16 Downgrades Overweight → Neutral
10/05/2021 1103.5% Morgan Stanley → $55 Downgrades Overweight → Equal-Weight
09/09/2021 1212.91% SVB Leerink → $60 Initiates Coverage On → Outperform
08/18/2021 709.63% Morgan Stanley $35 → $37 Maintains Overweight
06/03/2021 665.86% Morgan Stanley $82 → $35 Maintains Overweight
04/06/2021 1694.31% Morgan Stanley $49 → $82 Maintains Overweight
01/29/2021 1344.2% JP Morgan $45 → $66 Maintains Overweight
11/25/2020 Evercore ISI Group Initiates Coverage On → Outperform
11/24/2020 884.68% JP Morgan → $45 Initiates Coverage On → Overweight
11/24/2020 William Blair Initiates Coverage On → Outperform
11/24/2020 972.21% Morgan Stanley → $49 Initiates Coverage On → Overweight
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
2023年1月27日 31.29% SVB Leerink $8→$6 維護 市場表現
01/24/2023 -12.47% 摩根士丹利 $7→$4 維護 體重不足
2022年08月15日 53.17% 摩根士丹利 $6→$7 維護 體重不足
03/02/2022 75.05% 摩根大通 $10→$8 維護 中性
03/01/2022 96.94% SVB Leerink $10→$9 維護 市場表現
02/16/2022 118.82% SVB Leerink $11→$10 維護 市場表現
01/06/2022 53.17% 摩根士丹利 $14→$7 評級下調 等重→減碼
2021年11月18日 140.7% SVB Leerink →$11 評級下調 跑贏→市場表現
10/20/2021 337.64% SVB Leerink $60→$20 維護 跑贏大盤
10/20/2021 250.11% 摩根大通 $61→$16 評級下調 超重→中性
10/05/2021 1103.5% 摩根士丹利 →$55 評級下調 超重→等重
09/09/2021 1212.91% SVB Leerink →$60 開始承保 →跑贏大盤
2021/08/18 709.63% 摩根士丹利 $35→$37 維護 超重
06/03/2021 665.86% 摩根士丹利 $82→$35 維護 超重
04/06/2021 1694.31% 摩根士丹利 $49→$82 維護 超重
2021/01/29 1344.2% 摩根大通 $45→$66 維護 超重
11/25/2020 - Evercore ISI集團 開始承保 →跑贏大盤
11/24/2020 884.68% 摩根大通 →$45 開始承保 →超重
11/24/2020 - 威廉·布萊爾 開始承保 →跑贏大盤
11/24/2020 972.21% 摩根士丹利 →$49 開始承保 →超重

What is the target price for Atea Pharmaceuticals (AVIR)?

ATEA製藥(Avir)的目標價是多少?

The latest price target for Atea Pharmaceuticals (NASDAQ: AVIR) was reported by SVB Leerink on January 27, 2023. The analyst firm set a price target for $6.00 expecting AVIR to rise to within 12 months (a possible 31.29% upside). 6 analyst firms have reported ratings in the last year.

ATEA製藥(納斯達克:AVIR)的最新目標價是由SVB Leerink於2023年1月27日報道的。這家分析公司將目標價定為6.00美元,預計Avir將在12個月內上漲(可能上漲31.29%)。6家分析公司在過去一年公佈了評級。

What is the most recent analyst rating for Atea Pharmaceuticals (AVIR)?

分析師對安泰製藥(AVIR)的最新評級是多少?

The latest analyst rating for Atea Pharmaceuticals (NASDAQ: AVIR) was provided by SVB Leerink, and Atea Pharmaceuticals maintained their market perform rating.

ATEA製藥(納斯達克代碼:AVIR)的最新分析師評級由SVB Leerink提供,ATEA製藥維持其市場表現評級。

When is the next analyst rating going to be posted or updated for Atea Pharmaceuticals (AVIR)?

安泰製藥(Avir)的下一次分析師評級將於何時發佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atea Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atea Pharmaceuticals was filed on January 27, 2023 so you should expect the next rating to be made available sometime around January 27, 2024.

分析師在進行了廣泛的研究後得出了股票評級,其中包括查閱公共財務報表,與ATEA製藥公司的高管和客戶交談,以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。對ATEA製藥的上一次評級是在2023年1月27日提交的,所以你應該預計下一次評級將在2024年1月27日左右的某個時候公佈。

Is the Analyst Rating Atea Pharmaceuticals (AVIR) correct?

分析師對安泰製藥(AVIR)的評級正確嗎?

While ratings are subjective and will change, the latest Atea Pharmaceuticals (AVIR) rating was a maintained with a price target of $8.00 to $6.00. The current price Atea Pharmaceuticals (AVIR) is trading at is $4.57, which is out of the analyst's predicted range.

雖然評級是主觀的,並將發生變化,但最新的ATEA製藥(Avir)評級維持不變,目標價在8.00美元至6.00美元之間。ATEA製藥(Avir)目前的交易價格為4.57美元,超出了分析師的預測區間。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論